Stockscreener 앱 받기
1.91
3.24%
0.06
전일 마감가:
$1.85
열려 있는:
$1.792
하루 거래량:
32,243
Relative Volume:
0.33
시가총액:
$81.90M
수익:
$18.11M
순이익/손실:
$-18.95M
주가수익비율:
-4.3657
EPS:
-0.4375
순현금흐름:
-
1주 성능:
+1.32%
1개월 성능:
-4.98%
6개월 성능:
-15.11%
1년 성능:
-42.99%
1일 변동 폭
$1.79
$1.925
1주일 범위
$1.75
$2.12
52주 변동 폭
$1.74
$3.85
에이다진 Stock (ADAG) Company Profile
ADAG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
1.91 | 81.90M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.83 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.50 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.38 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.34 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.02 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
에이다진 Stock (ADAG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-06-25 | 개시 | China Renaissance | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
에이다진 주식(ADAG)의 최신 뉴스
FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World
FY2029 Earnings Forecast for Adagene Issued By HC Wainwright - Defense World
FY2024 Earnings Forecast for Adagene Issued By HC Wainwright - MarketBeat
FY2029 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
HC Wainwright Forecasts Strong Price Appreciation for Adagene (NASDAQ:ADAG) Stock - MarketBeat
H.C. Wainwright lifts Adagene stock target to $8 on ASCO data - Investing.com
Adagene reports positive colorectal cancer trial results - Investing.com India
ADAGAdagene Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adagene Reports Promising Results in Colorectal Cancer Study - TipRanks
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - The Manila Times
Adagene's Muzastotug Shows 33% Response Rate in Colorectal Cancer Trial - StockTitan
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Adagene to present new ADG126 clinical data at ASCO-GI By Investing.com - Investing.com Australia
Adagene to Announce Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene to Present New ADG126-KEYTRUDA Combo Data for Colorectal Cancer at ASCO GI Symposium - StockTitan
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 - Wahanariau
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 - GlobeNewswire
Adagene Hosts Expert Panel on Breakthrough Cancer Treatment ADG126 for Colorectal Cancer - StockTitan
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Short Interest in Adagene Inc. (NASDAQ:ADAG) Increases By 88.2% - MarketBeat
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Fmr LLC Has $2.84 Million Stock Holdings in Adagene Inc. (NASDAQ:ADAG) - Defense World
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Short Interest in Adagene Inc. (NASDAQ:ADAG) Drops By 87.8% - Defense World
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Anheuser-Busch InBev S.A. ADR falls Monday, underperforms market - MSN
Algorae Pharmaceuticals Streamlines Operations with OTCQB Exit - MSN
Anheuser-Busch InBev S.A. ADR falls Tuesday, underperforms market - MSN
Adagene shares downgraded to hold, target cut to $3.50 - Investing.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Decline in Short Interest - MarketBeat
Anheuser-Busch InBev S.A. ADR falls Friday, underperforms market - MSN
Adagene reports new findings at SITC meeting By Investing.com - Investing.com Canada
Adagene reports new findings at SITC meeting - Investing.com India
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 T - Wahanariau
Adagene Presents Two Posters with New Insights on Increased - GlobeNewswire
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times
Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat
Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC - Investing.com
에이다진 (ADAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):